The Effct of Chitooligosaccharide on Immune Function in Healthy Adults

This study has been completed.
Sponsor:
Information provided by:
Eulji University Hospital
ClinicalTrials.gov Identifier:
NCT00468962
First received: May 2, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
  Purpose

Functional properties of chitooligosaccharides have been studied for antitumor activity, immunostimulating effects, antimicrobial activity, free radical scavening activity, adn angiotensin I converting enzyme inhibitory activity. Recent in vitro, and in vivo toxicity and absorbability studies have demonstrated that chitooligosaccharides have high absorbability and are essentially non-toxic. In the present study, we prepared a chitooligosaccharide with high absorbability and evaluated its effects on activation of immune function and cardiovascular funciton(lipid, atrial stiffness, etc) in healthy adults.

This study was a 8-week, randomized, double-blind clinical trial. The 30 volunteers were divided into a control group(n=10), half dose chitooligosaccaride(FACOSTM) intake group(n=10), and full dose FACOS intake group(n=10). Peripheral blood mononuclear cells(PBMCs) were isolated and cultured in 12 well plate for 48 hours. Cytokine production by PBMCs pre- and postintervention were measured simultaneously after stimulation with lipopolysaccaride.


Condition Intervention Phase
Immunity
Drug: FACOS (functional food)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Further study details as provided by Eulji University Hospital:

  Eligibility

Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • healthy adults(the ages between 20~50 year)

Exclusion Criteria:

  • food allergy and allergy skin disease
  • severe liver and kidney disease
  • pregnant, lactating women
  • cancer, stroke, etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00468962

Sponsors and Collaborators
Eulji University Hospital
Investigators
Principal Investigator: Hee-Jeong Choi, MD, Ph.D Eulji University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00468962     History of Changes
Other Study ID Numbers: 07-05
Study First Received: May 2, 2007
Last Updated: May 2, 2007
Health Authority: Korea: Food and Drug Administration

ClinicalTrials.gov processed this record on October 23, 2014